Loading...
XJPX
4582
Market cap19mUSD
Oct 09, Last price  
54.00JPY
1D
-1.82%
1Q
-23.94%
Jan 2017
-94.47%
IPO
-95.91%
Name

SymBio Pharmaceuticals Ltd

Chart & performance

D1W1MN
XJPX:4582 chart
P/E
—
P/S
2.28
EPS
—
Div yield, %
—
Shrs. gr., 5y
8.79%
Rev. gr., 5y
-15.23%
Revenues
1.31b
-46.69%
1,630,029,0001,191,127,0001,449,972,0001,882,521,0001,955,178,0001,532,054,0001,955,027,0001,933,241,0002,368,112,0003,444,206,0003,835,530,0002,837,753,0002,987,051,0008,252,582,00010,008,338,0005,589,708,0002,452,912,0001,307,648,000
Net income
-4.78b
L+24.59%
20,987,000-217,872,000-642,307,000-2,104,513,000-1,733,320,000-1,605,224,000-1,115,877,000-2,632,095,000-2,313,233,000-3,977,862,000-2,752,533,000-4,376,258,000-4,090,216,0002,032,203,0001,179,238,000-1,962,817,000-3,833,480,000-4,776,194,000
CFO
-4.58b
L+33.92%
154,387,000-211,336,000-753,971,000-2,074,057,000-1,658,588,000-1,677,348,000-1,266,174,000-2,271,686,000-1,960,089,000-3,816,793,000-2,324,547,000-4,350,738,000-4,122,483,000140,042,0001,614,241,000-194,685,000-3,416,518,000-4,575,568,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

SymBio Pharmaceuticals Limited engages in the and development, manufacturing and sales of pharmaceuticals and other related operations in Japan and internationally. It offers SyB V-1901, an antiviral drug for post-transplant infections, blood cancers and solid tumors, and neurodegenerative diseases; SyB L-1701, an RTD liquid formulation; and SyB L-1702, an RI administration under the TREAKISYM name. The company was incorporated in 2005 and is based in Minato, Japan.

Key people

Fuminori Yoshida
President, Executive President, Chief Executive Officer, Representative Director · since 2005
Takaaki Fukushima
Chief Financial Officer, Executive Vice President · since 2024
Noritaka Narimiya
Managing Executive Officer, Chief Financial Officer · since 2025
Ken Taguchi
Executive Vice President, Chief Operating Officer · since 2025
Shunichi Sasaki
Managing Executive Officer · since 2024
Masatoshi Hazama
Executive Officer, CSO · since 2025
Paul Marston
Executive Officer, General Counsel · since 2024
Minori Rosales
Executive Officer, Chief Medical Officer, Chief Director of Japan Development · since 2026
Bruce Cheson
Independent Director · since 2019
Eiji Ebinuma
Independent Director · since 2021
Kesao Endo
Independent Director · since 2022
Toshio Imabeppu
Independent Director · since 2024
Shigetoshi Matsumoto
Independent Director · since 2018
Koichi Shimomura
Independent Director · since 2025
Ralph Smalling
Independent Director · since 2025
Yasuhiro Tamo
Independent Director · since 2022
Takashi Watanabe
Independent Director · since 2025
Kiyoshi Watanabe
Independent Director · since 2022
URL
https://www.symbiopharma.com/
IPO date
Oct 20, 2011
Employees
122
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT